Effect of Lactulose and/or Polyethylene Glycol Solution for Bowel Preparation for Colonscopy Procedures

Sponsor
Sichuan University (Other)
Overall Status
Recruiting
CT.gov ID
NCT05076799
Collaborator
Affiliated Hospital of Southwest Medical University (Other), Affiliated Hospital of North Sichuan Medical College (Other)
1,000
1
4
12
83.6

Study Details

Study Description

Brief Summary

Colonoscopy is the most useful exam used to evaluate colorectal diseases, like colorectal polyps and cancer. The appropriate bowel preparation is indispensable for colonoscopy procedures. Polyethylene glycol solution (PEG) is the most frequent laxative medication. However, the taste is poor, and patients need to drink a lot of liquids to obtain adequate visualization of the mucosal surface. In fact, no laxative has all the characteristics of an ideal medication. Lactulose is an osmotic laxative which widely used in cirrhosis and constipation patients, and could inhibit bacterial in the colon to increase colon cleanliness and prolong the effect time of PEG. Previous study demonstrate PEG combined with lactulose has a significant improvement in the quality of bowel preparation compared with PEG alone. The present study aim to assess the efficacy of lactulose with or without PEG in bowel preparation to improve mucosal visualization, reduced volume of fluid consumed, and preparation intolerance.

Condition or Disease Intervention/Treatment Phase
  • Drug: 100 ml lactulose combined with 1 L PEG
  • Drug: 100 ml lactulose combined with 2 L PEG
  • Drug: 200 ml lactulose
  • Drug: 3 L Polyethylene glycol solution
Phase 3

Detailed Description

This study will conduct in 5 clinical central. 1000 participants who were scheduled for colonoscopy age between 18 and 80 years were enrolled in the study. Exclusion criteria were patients with uncontrolled acute or recurrent chronic intestinal infections, with active gastrointestinal bleeding or gastrointestinal stricture or intestinal obstruction, with severity coronary heart disease or heart failure or renal failure and liver failure or severe electrolyte metabolism disorder, with pregnant or lactating or metal diseases or refuse to colonoscopy examination. Central stratification and block randomization is achieved via a computer-generated random-sequence table by using R software. The participants will be assigned into one of four groups at a ratio of 1 : 1, and received a single 3 L dose of either PEG or 200ml dose of lactulose, 100ml lactulose combined with 1L PEG, 100ml lactulose combined with 2L PEG. The following parameters were then obtained: time of the first defecation, defecation frequency, the overall drink liquid volume, the taste of the preparation, the tolerance evaluation, the cleansing quality of the bowel preparations and adverse reaction.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
1000 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Single (Outcomes Assessor)
Primary Purpose:
Diagnostic
Official Title:
Effect of Lactulose and/ or Polyethylene Glycol Solution for Bowel Preparation in Colonscopy: a Multi-center Prospective Randomized Study
Actual Study Start Date :
Sep 1, 2021
Anticipated Primary Completion Date :
May 31, 2022
Anticipated Study Completion Date :
Aug 31, 2022

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: 3 L Polyethylene glycol solution group

The participants were instructed to consume 3000 mL of PEG solution

Drug: 3 L Polyethylene glycol solution
the participants were instructed to consume 3000 mL of PEG solution
Other Names:
  • control group
  • PEG group
  • Experimental: 100 ml lactulose combined with 1 L PEG group

    the participants were instructed to consume 100 ml lactulose combined with 1000 mL of PEG solution

    Drug: 100 ml lactulose combined with 1 L PEG
    the participants were instructed to consume 100 ml lactulose combined with 1000 mL of PEG solution
    Other Names:
  • lactulose and 1 L PEG group
  • Experimental: 100 ml lactulose combined with 2 L PEG group

    the participants were instructed to consume 100 ml lactulose combined with 2000 mL of PEG solution

    Drug: 100 ml lactulose combined with 2 L PEG
    the participants were instructed to consume 100 ml lactulose combined with 2000 mL of PEG solution
    Other Names:
  • lactulose and 2 L PEG group
  • Experimental: 200 ml lactulose group

    the participants were instructed to consume 200 ml lactulose

    Drug: 200 ml lactulose
    the participants were instructed to consume 200 ml lactulose alone
    Other Names:
  • lactulose group
  • Outcome Measures

    Primary Outcome Measures

    1. The quality of bowel preparation [up to 12 months]

      to assess the quality of bowel preparation by using Boston Bowel Preparation Scale. The minimum score value is 0,and the maximum value is 9. A higher score means a better outcome. Bowel cleansing was scored by the endoscopist performing the colonoscopy in the single-blind method.

    2. The preparation intolerance [up to 12 months]

      to assess the preparation intolerance including the palatability of the bowel-cleansing agents, the general satisfaction with the bowel preparation, the willingness to perform another colonoscopy by using case report questionnaire. Moreover, the ratio of drink all preparation fluids and the specific amount of bowel preparation fluid are documented.

    Secondary Outcome Measures

    1. The colorectal diseases detection rate [up to 12 months]

      the cecal intubation time, colonoscopy perform time, and polyp detection rate or colorectal cancer detection rate are recorded.

    2. The adverse events [up to 12 months]

      the adverse events including nausea, vomiting, abdominal pain, abdominal distension, and other adverse reactions after administration are evaluated.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years to 80 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    Yes
    Inclusion Criteria:
    • Participants who were scheduled for colonoscopy age between 18 and 80 years
    Exclusion Criteria:
    • uncontrolled acute or recurrent chronic intestinal infections

    • active gastrointestinal bleeding, gastrointestinal stricture, intestinal obstruction

    • severe electrolyte metabolism disorder, severe coronary heart disease, heart failure, renal failure or liver failure

    • pregnant, lactating, have metal diseases or refuse to colonoscopy examination

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 west china fourth hospital of Sichuan university Chendu Sichuan China 610014

    Sponsors and Collaborators

    • Sichuan University
    • Affiliated Hospital of Southwest Medical University
    • Affiliated Hospital of North Sichuan Medical College

    Investigators

    • Study Director: juan liao, PhD, West China Forth Hospital

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Lin Cai, Principal Investigator, Sichuan University
    ClinicalTrials.gov Identifier:
    NCT05076799
    Other Study ID Numbers:
    • Sichuan U
    First Posted:
    Oct 13, 2021
    Last Update Posted:
    Oct 13, 2021
    Last Verified:
    Sep 1, 2021
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by Lin Cai, Principal Investigator, Sichuan University
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Oct 13, 2021